Phase Ib Evaluation of the Safety and Tolerability and Effect on Midazolam Metabolism of the Administration of Multiple Rising Doses of BI 730357 to Healthy Volunteers.

Trial Profile

Phase Ib Evaluation of the Safety and Tolerability and Effect on Midazolam Metabolism of the Administration of Multiple Rising Doses of BI 730357 to Healthy Volunteers.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs BI 730357 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 27 Nov 2017 Planned initiation date changed from 15 Nov 2017 to 11 Dec 2017.
    • 18 Oct 2017 Planned End Date changed from 20 Apr 2019 to 19 May 2018.
    • 18 Oct 2017 Planned primary completion date changed from 14 Apr 2018 to 12 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top